BAUSCH + LOMB CORP
BLCONYSETrading Snapshot
- Day Range
- $18.52 β $20.43
- 52-Week Range
- $14.44 β $18.92
- Volume (shares)
- 266,271
- Avg Volume (shares)
- β
- Shares Outstanding
- 357.4M
- Next Earnings
- 2026-10-28
Fundamentals Snapshot
- Annual Revenue
- $5.10B
- Last Q Revenue
- $1.39B
- P/E Ratio
- β
- P/S Ratio
- 1.2x
- EPS (TTM)
- $-0.48
- Dividend Yield
- β
- Dilution (1yr)
- +0.7%
BAUSCH + LOMB CORP
BLCOAbout BAUSCH + LOMB CORP
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
News unavailable.